Welcome to our dedicated page for Milestone Pharmaceuticals SEC filings (Ticker: MIST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Milestone Pharmaceuticals Inc. filings document a commercial-stage biopharmaceutical company focused on cardiovascular medicines, including CARDAMYST (etripamil) nasal spray for adults with PSVT. Its 8-K filings report financial results, commercial launch updates, regulatory and corporate updates, Regulation FD presentations and material events related to etripamil.
The filing record also covers Milestone's Nasdaq-listed common shares, proxy governance for annual shareholder meetings, board and voting matters, and capital-structure items such as the completed sale of a royalty interest tied to U.S. etripamil net product sales. These disclosures provide formal records of operating results, governance, financing arrangements and product-related corporate events.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) has launched a high-dilution capital raise via a Rule 424(b)(5) prospectus supplement. The company is offering 31,500,000 common shares and, for investors that elect, 3,502,335 pre-funded warrants, each unit paired with one Series A and one Series B common warrant. The combined public offering price is $1.50 per common share unit and $1.499 per pre-funded warrant unit, implying only a modest 3.8 % discount to the prior $1.56 closing price (11 July 2025).
The package delivers:
- Gross proceeds: $52.5 million
- Underwriting fees: $3.15 million (6.0%)
- Estimated net proceeds: ≈ $48.7 million after offering expenses
- New share count: 84,964,273 basic shares post-offering (up 59%)
Warrants provide additional leverage. Series A warrants (exercise $1.50) expire in one year; Series B warrants (exercise $1.875) run five years and include a forced-exercise feature once the stock trades ≥ $3.50 for 10 consecutive days. If fully exercised for cash, the warrants could yield a further $118.1 million.
Use of proceeds. Management will direct funds to commercial readiness and continued clinical development of etripamil (CARDAMYST), its intranasal calcium-channel blocker for paroxysmal supraventricular tachycardia (PSVT) and AFib-RVR, plus general corporate purposes. Cash, equivalents and short-term investments were $56.0 million at 31 Mar 2025 and a preliminary $43.4 million at 30 Jun 2025; the raise extends liquidity into 2026.
Regulatory status. The FDA issued a Complete Response Letter in March 2025, citing CMC issues. Milestone submitted a response that was accepted 11 Jul 2025, setting a new PDUFA action date of 13 Dec 2025. Approval before 31 Dec 2025 would also trigger a $75 million royalty monetisation from RTW Investments (deadline recently extended).
Dilution & capital structure. The offering increases outstanding shares by ~31.5 million (plus up to 35 million additional warrant shares), on top of 53.5 million existing. Outstanding options (7.8 million), legacy pre-funded warrants (12.9 million) and convertible notes (up to 15.7 million shares) add further potential dilution. Pro-forma tangible book value turns positive at $0.47/sh, but immediate dilution to new buyers is $1.03/sh.
Key risks. The raise is contingent on no guarantees of FDA approval; warrants create overhang; absence of warrant listing limits liquidity; the company remains pre-revenue and subject to clinical, regulatory and execution risks detailed under “Risk Factors”.
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) filed an 8-K on 10 July 2025 disclosing two material events:
- Royalty Purchase Agreement Amendment (Item 1.01): The Company and RTW Royalty I DAC agreed to extend the Marketing Approval Deadline for etripamil from 30 Sep 2025 to 31 Dec 2025. The amendment provides Milestone with an additional three months to secure U.S. marketing approval before contractual milestone or repayment provisions are triggered. Full terms will be included in the next periodic filing.
- Regulatory Update (Item 8.01): On 11 July 2025 the FDA accepted Milestone’s complete response to the prior Complete Response Letter for its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray targeting paroxysmal supraventricular tachycardia. The agency set a new Prescription Drug User Fee Act (PDUFA) action date of 13 Dec 2025.
Investment view: FDA acceptance and a defined PDUFA date re-start the approval clock, reducing regulatory uncertainty and acting as an upside catalyst. The three-month extension in the royalty agreement aligns contractual timelines with the new PDUFA date, avoiding potential covenant breaches. No financial statements were included, but successful approval would unlock royalty financing and potential commercialization revenue.
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) filed an 8-K on 10 July 2025 disclosing two material events:
- Royalty Purchase Agreement Amendment (Item 1.01): The Company and RTW Royalty I DAC agreed to extend the Marketing Approval Deadline for etripamil from 30 Sep 2025 to 31 Dec 2025. The amendment provides Milestone with an additional three months to secure U.S. marketing approval before contractual milestone or repayment provisions are triggered. Full terms will be included in the next periodic filing.
- Regulatory Update (Item 8.01): On 11 July 2025 the FDA accepted Milestone’s complete response to the prior Complete Response Letter for its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray targeting paroxysmal supraventricular tachycardia. The agency set a new Prescription Drug User Fee Act (PDUFA) action date of 13 Dec 2025.
Investment view: FDA acceptance and a defined PDUFA date re-start the approval clock, reducing regulatory uncertainty and acting as an upside catalyst. The three-month extension in the royalty agreement aligns contractual timelines with the new PDUFA date, avoiding potential covenant breaches. No financial statements were included, but successful approval would unlock royalty financing and potential commercialization revenue.
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) filed an 8-K on 10 July 2025 disclosing two material events:
- Royalty Purchase Agreement Amendment (Item 1.01): The Company and RTW Royalty I DAC agreed to extend the Marketing Approval Deadline for etripamil from 30 Sep 2025 to 31 Dec 2025. The amendment provides Milestone with an additional three months to secure U.S. marketing approval before contractual milestone or repayment provisions are triggered. Full terms will be included in the next periodic filing.
- Regulatory Update (Item 8.01): On 11 July 2025 the FDA accepted Milestone’s complete response to the prior Complete Response Letter for its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray targeting paroxysmal supraventricular tachycardia. The agency set a new Prescription Drug User Fee Act (PDUFA) action date of 13 Dec 2025.
Investment view: FDA acceptance and a defined PDUFA date re-start the approval clock, reducing regulatory uncertainty and acting as an upside catalyst. The three-month extension in the royalty agreement aligns contractual timelines with the new PDUFA date, avoiding potential covenant breaches. No financial statements were included, but successful approval would unlock royalty financing and potential commercialization revenue.